A-86929 is a synthetic compound that acts as a selective dopamine receptor D1 agonist.[1][2] It was developed as a possible treatment for Parkinson's disease,[3] as well as for other applications such as treatment of cocaine addiction,[4][5] but while it had reasonable efficacy in humans it also caused dyskinesias and has not been continued.[6][7] It has mainly been used as its diacetate ester prodrug adrogolide (ABT-431), which has better bioavailability.[8][9]
Names | |
---|---|
Preferred IUPAC name
(5aR,11bS)-2-Propyl-4,5,5a,6,7,11b-hexahydrobenzo[f]thieno[2,3-c]quinoline-9,10-diol | |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEMBL |
|
ChemSpider |
|
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C18H21NO2S | |
Molar mass | 315.429 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is ?)
Infobox references
|